Clinical trials: Oral Antineoplastic Agents
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Adherence, Patient, Cancer
Impact of Changing the Appearance of Oral Antineoplastics on Adherence and Continuity of Treatment, Patient-reported Health Outcomes, and Patient Experience of Care
Oral chemotherapy is a convenient and flexible option for cancer treatment that can improve patients quality of life and increase adherence to treatment compared to traditional intravenous chemotherapy.
- Trial name
- NCT07664683
- Where
- Spain
- Volunteers
- 334 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Male Hypogonadism
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
- Trial name
- SOAR (NCT02081300)
- Testing
- Oral testosterone undecanoate, LPCN 1021, Topical testosterone gel 1.62 %
- Volunteers
- 315 people
- Sponsor
- Lipocine Inc.
Mucositis
Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis
The treatment of cancer in children may result in an extremely painful condition called oral mucositis when the cells lining the mouth are injured due to the cancer medication.
- Trial name
- NCT00474110
- Testing
- Ketamine & hydromorphone
- Where
- Canada
- Sponsor
- University of British Columbia
Cancer, Atrial Fibrillation
Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy
- Trial name
- MAFIC (NCT04508855)
- Testing
- Low molecular weight heparin
- Where
- 2 sites in Greece
- Sponsor
- AHEPA University Hospital
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy
Statement of problem Oral mucositis is an inflammatory condition that affects mucosa of the oral cavity. The etiology of this kind of aggravation is related to the introduction of radiotherapy or chemotherapeutic medications.
- Trial name
- NCT03613389
- Testing
- oral topical vitamin E
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Cairo University
Sarcoma, Kaposi, HIV Infections
A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population.
- Trial name
- NCT00002314
- Testing
- Ro 24-7429
- Where
- 2 sites in United States
- Sponsor
- Hoffmann-La Roche
Antineoplastic Agents
Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?
This study is being conducted by Bassett Healthcare Network in coordination with Bassett Cancer Institute. Patients prescribed oral chemotherapies will be approached to consider consent to this study.
- Trial name
- NCT02468245
- Testing
- weekly telephone follow up, usual care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bassett Healthcare
Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Prevention of Oral Mucositis After Using Chamomile Oral Cryotherapy Versus Oral Cryotherapy in Pediatric Cancer Patients Receiving Chemotherapy.
oral mucositis is a painful situation that significantly affects patients' quality of life with the severe cases being associated with ulcerated mucosa and secondary infection which may lead to life-threatening sepsis.Chamomile…
- Trial name
- NCT03605186
- Testing
- Chamomile oral cryotherapy, Oral cryotherapy
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cairo University
Breast Cancer
Increasing Oral Medication Adherence for Metastatic Breast Cancer Patients
Aim of this study is to optimize an adherence increasing intervention designed for metastatic Breast Cancer (BC) patients by applying a full factorial design in order to evaluate the optimal combination of three different…
- Trial name
- NCT06726889
- Testing
- Standard care, Decision Support System (DSS), Reminders
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- European Institute of Oncology
Adherence, Medication
DESIGN OF A SCALE TO MEASURE COMPLIANCE WITH DRUG TREATMENT IN PATIENTS WITH ORAL CHEMOTHERAPY
Introduction: In recent years, there has been an increase in the use of oral chemotherapy, for its comfort and for allowing a higher quality of life.
- Trial name
- NCT04550533
- Testing
- Therapeutic Adherence
- Volunteers
- 288 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Sarcoma, Kaposi, HIV Infections
A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00002188
- Testing
- Alitretinoin
- Volunteers
- 27 people
- Sponsor
- Anderson Clinical Research
Adults, Hematological Malignancy
A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting
Patients with haematologic malignancies are increasingly treated by Oral Anticancer Medications (OAMs), increasing the challenge of ensuring optimal adherence to treatment.
- Conditions
- Adults, Hematological Malignancy, Oral Antineoplastic Agents
- Trial name
- MADESIO (NCT04613765)
- Testing
- Measure adherence behaviors
- Where
- 2 sites in Belgium
- Volunteers
- 113 people
- Sponsor
- Jules Bordet Institute
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Anemia
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving…
- Trial name
- NCT00224068
- Testing
- Sodium ferric gluconate, ferrous sulfate, standard of care
- Where
- 32 sites in United States
- Volunteers
- 180 people
- Sponsor
- Watson Pharmaceuticals
Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Construction and Preliminary Application of Evidence-Based Nursing Protocol for Oral Mucositis Related to Tumor Therapy
Describe the incidence and influencing factors of cancer therapy-related oral mucositis. Based on evidence-based practice, develop a standardized nursing protocol for cancer therapy-related oral mucositis that aligns with China's…
- Trial name
- NCT07305766
- Testing
- Intervention group, Conventional nursing measures
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking Union Medical College
Neoplasms, Colorectal, Solid Tumor
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Conditions
- Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
- Trial name
- SYLVER (NCT06710847)
- Testing
- GSK4418959, PD-1 inhibitor
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
ER-Positive HER2-Negative Breast Cancer
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone…
- Trial name
- SERENA-4 (NCT04711252)
- Testing
- AZD9833, Anastrozole, Palbociclib
- Where
- 263 sites in United States, Austria and 25 more
- Volunteers
- 1,371 people
- Sponsor
- AstraZeneca